Background {#Sec1}
==========

Traumatic cartilage injury can lead to the development of osteoarthritis (OA) \[[@CR1]\]. Autologous chondrocyte implantation (ACI) has been adopted clinically to repair cartilage damage \[[@CR2], [@CR3]\] and is a procedure that involves two surgeries. The first is to harvest cartilage from a minor load-bearing region of the joint (Stage I), followed by a 3--4 week chondrocyte extraction and culture expansion phase, and the second procedure (Stage II) occurs when chondrocytes are implanted into the pathological cartilage defect \[[@CR3], [@CR4]\]. Within our centre, the procedure has a 19% failure rate, as defined by a lack of improvement in Lysholm score \[[@CR5]\], which is comparable to other centres \[[@CR6], [@CR7]\]. Demographic- and injury-associated risk factors for failure have been identified \[[@CR8]--[@CR10]\]; however, currently there is little understanding of the biological nature of ACI failure. We hypothesise that an individual's probability of failure to respond to ACI can be predicted, and that the metrics required to make such a prediction will come from improved understanding of the pathology of the failure in the first instance. Further, we aim to address the need to identify putative biomarkers that can be used to predict patient long-term outcome prior to cartilage repair therapy. The importance of this has been highlighted by the Osteoarthritis Research Society International (OARSI) who published guidelines highlighting the need "to determine whether biomarkers are useful in identifying those individuals most likely to receive clinically important benefits from an intervention; and to determine whether biomarkers are useful for identifying individuals at earlier stages of OA in order to institute treatment at a time more amenable to disease modification" \[[@CR11]\]. The synovial fluid (SF) surrounding the ACI repair site provides a biological fluid that can be assessed to profile the joint environment and to investigate the biological response and innate repair following a 'controlled injury', such as that which is sustained at Stage I of the ACI procedure. Despite strong evidence that unbiased proteomic approaches can identify novel biomarkers of OA progression (reviewed in De Ceuninck and Berberbaum \[[@CR12]\] and Hsueh et al. \[[@CR13]\]), relatively few studies have focused on the SF \[[@CR14], [@CR15]\]. The limited numbers of studies that have analysed human SF proteins in cartilage injury and repair have tested for markers of OA of known biological relevance to cartilage injury \[[@CR16]--[@CR19]\]. Using a targeted approach to biomarker identification, our group has been able to demonstrate that the absence of detectable aggrecanase-1 activity in the SF can be used along with lower age and higher baseline knee function as a predictive marker of ACI success \[[@CR19]\], indicating that SF biomarkers have the potential for the stratification of patients to appropriate cartilage repair therapies. We are unaware of any published work that has used an untargeted approach to investigate the SF proteome before, during, or after an intervention to treat cartilage injury. There is therefore a requirement to complete an unbiased assessment to identify putative predictive biomarkers that may allow for ACI patient stratification.

The broad dynamic range of proteins in SF \[[@CR20], [@CR21]\] means that abundant proteins can make it difficult to interrogate low abundance proteins by suppressing their detectability. The deepest examination of the SF proteome to date (equine SF) \[[@CR21]\] used hexapeptide libraries \[[@CR22], [@CR23]\] to capture low abundance proteins. In this publication, we have profiled the SF proteome from patients undergoing ACI treatment at both stages of the procedure using dynamic range compression with hexapeptide libraries and label-free quantification proteomics by liquid chromatography/tandem mass spectrometry (LC-MS/MS).

Methods {#Sec2}
=======

Synovial fluid collection and storage {#Sec3}
-------------------------------------

Following local research ethical committee approval and with informed consent, SF was collected from the knee joints of patients at Stages I (harvest; 15 samples) and II (implantation of cells; 24 samples) of ACI by injecting 20 mL of saline and then extending and flexing the leg at least 20 times prior to intra-articular aspiration of as much SF as possible \[[@CR24]\]. SF was then centrifuged at 6000 g for 15 mins at 4 °C before being divided into aliquots and stored in --196 °C liquid nitrogen prior to analyses. Prior to selection of suitable patient samples for this study, the dilution factor of the SFs was assessed by measurement of urea concentrations in the SF and plasma (harvested at the same time). Based on evidence that the urea concentration of plasma and SF is equivalent, the dilution factor could then be calculated as described previously \[[@CR19], [@CR25]\]. Any samples with a dilution factor over 10 were excluded from the study.

As has previously been used \[[@CR26]--[@CR28]\], we defined responders as a minimal clinically important difference (MCID) at approximately 12 months post-treatment if they had an increase of 10 points in the Lysholm score (which ranges from 0--100, with 100 representing 'perfect' knee function \[[@CR29]\]). Fourteen SF donors were considered as responders, with a mean improvement of 33 points (range 17--54) and 13 SF donors were considered as non-responders with a mean decrease in Lysholm score of 14 points (range 4--46). Matched Stage I and II samples were included for seven responders and six non-responders; however, all of the proteomic data presented in this study are based on non-matched statistical comparisons to ensure the maximal number of patient samples could be included in each comparison. The demographic information and change in Lysholm score for these patients is shown in Table [1](#Tab1){ref-type="table"}. None of the demographic parameters, other than difference in Lysholm score between baseline and 12 months post-ACI, were significantly different between responders and non-responders at Stage I or Stage II, or between Stage I and Stage II in responders or non-responders (*p* \> 0.05; Mann-Whitney *U* test; Table [1](#Tab1){ref-type="table"}).Table 1Demographic data for patient participants whose samples from Stage I or Stage II were analysed who responded clinically (responders) or who did not respond (non-responders) to autologous chondrocyte implantation (ACI)Stage IStage II*p* value (A) R v NR SI; (B) R v NR SI*p* value (A) SI v SII R; (B) SI v SII NRResponders (*n* = 8)Non-responders (*n* = 7)Responders (*n* = 12)Non-responders (*n* = 12)Difference in Lysholm Score27 (17--38)--8 (--4 to --17)34 (17--54)--11 (--4 to --46)(A) 0.0003; (B) \<0.0001(A) 0.21; (B) 0.55BMI (kg/m^2^)29 (23--31)27 (24--31)27 (23--48)29 (22--36)(A) 0.94; (B) 0.54(A) 0.73; (B) 0.68Age (years)32 (17--49)40 (25--50)40 (17--90)43 (25--52)(A) 0.28; (B) 0.92(A) 0.17; (B) 0.58Male (*n*)871110(A) \>0.99; (B) \>0.99(A) \>0.99; (B) 0.51Smoker (*n*)1213(A) 0.54; (B) 0.59(A) \>0.99; (B) \>0.99Dilution factor of SF5 (3--9)4 (2--7)4 (1--9)3 (2--5)(A) 0.48; (B) 0.25(A) 0.53; (B) 0.50Total defect area (cm^2^)14 (0.4--24)6 (0.6--12)6 (1--20)5 (0.6--12)(A) 0.74; (B) 0.35(A) 0.45; (B) 0.28Patella defect (*n*)1142(A) \>0.99; (B) 0.64(A) 0.60; (B) \>0.99LFC defect (*n*)2000(A) 0.47; (B) \>0.99(A) 0.15; (B) \>0.99LTP defect (*n*)1000(A) \>0.99; (B) \>0.99(A) 0.15; (B) \>0.99MFC defect (*n*)2216(A) \>0.99; (B) 0.07(A) 0.54; (B) 0.63Trochlea defect (*n*)0321(A) 0.20; (B) \>0.99(A) 0.49; (B) 0.12Multiple defects (*n*)1011(A) \>0.99; (B) \>0.99(A) \>0.99; (B) \>0.99Unknown defect location (*n*)1142(A) \>0.99; (B) 0.64(A) 0.60; (B) \>0.99None of the demographic parameters, other than difference in Lysholm scores, showed differences between responders (*R*) and non-responders (*NR*) in individuals whose synovial fluids (*SFs*) from Stage I (*SI*) or Stage II (*SII*) were compared, nor were there differences between individuals who were either responders or non-responders when comparing Stage I and Stage II samples (*p* ≥ 0.05; Mann-Whitney *U* test). Data are shown as median (range) unless otherwise indicated. *BMI* body mass index, *LFC* lateral femoral condyle, *LTP* lateral tibial plateau, *MFC* medial femoral condyle

Sample preparation and analysis using label-free proteomics {#Sec4}
-----------------------------------------------------------

All SF samples were maintained as separate samples throughout the protein equalisation, mass spectrometry, and label-free quantification steps, and no pooling of any samples was performed; hence, the abundance of proteins was quantified for each of the 39 samples and mean protein abundance across the experimental groups was calculated prior to analysis of protein changes.

### SF preparation and protein equalisation using ProteoMiner™ {#Sec5}

The dynamic range of proteins in SF was compressed using ProteoMiner™ beads (BioRad, Hemel Hempstead, UK) as described previously \[[@CR21]\]. Briefly, SF was treated with hyaluronidase (1 mg/ml) \[[@CR21], [@CR30]\] and digestion was confirmed using a Coomassie stained 1D-SDS PAGE gel. Total protein was quantitated using a Pierce™ 660-nm protein assay (Thermo Scientific, Hemel Hempstead, UK) \[[@CR31]\] and 5 mg of total protein was exposed to ProteoMiner™ beads. After washing, bead-bound proteins were treated with 0.05% (w/v) RapiGest (Waters, Manchester, UK) in 25 mM ammonium bicarbonate for 10 min at 80 °C prior to reduction, alkylation, and in-situ protein digestion without removal of the beads, ensuring complete proteome access. The digestion was completed in LoBind protein tubes (Eppendorf, Stevenage, UK) followed by acidification of trifluoroacetic acid to a final concentration of 0.5% (v/v). This treatment inactivates and precipitates the Rapigest detergent which can then be removed by centrifugation. The peptide-containing supernatant fractions were frozen at --20 °C prior to LC-MS/MS.

### Mass spectrometry and label-free quantification {#Sec6}

Tryptic peptides were subjected to LC-MS/MS, analysed using a 2-h gradient on a NanoAcquity™ ultraperformance LC (Waters, Manchester, UK) coupled online to a Q-Exactive Quadrupole-Orbitrap instrument (Thermo-Fisher Scientific Hemel Hempstead, UK) as described previously \[[@CR32]\]. For label-free quantification, the raw files of the acquired spectra were analysed by the ProgenesisQI™ software (Waters, Manchester, UK) \[[@CR33]\]. Briefly, the top five spectra for each feature were exported from ProgenesisQI™ and utilised for peptide identification with a locally implemented Mascot server (Version 2.3.01), searching against the Unihuman reviewed database. Search parameters used were: peptide mass tolerances, 10 ppm; fragment mass tolerance, 0.01 Da; 2+ and 3+ ions; missed cleavages, 1; enzyme, trypsin; instrument type, ESI-FTICR. Modifications included were: fixed carbamidomethyl cysteine and variable oxidation of methionine, lysine, and proline. To maximise the number of quantifiable proteins but simultaneously use an acceptable false discovery rate (FDR), the peptide matches above an identify-threshold were adjusted to give an FDR of 1% before the protein identifications were re-imported into ProgenesisQI™ for the label-free relative quantification. Quantification was undertaken using unique peptides only. Statistical analysis was performed using ProgenesisQI™ software; briefly transformed normalised abundances were used for one-way analysis of variance (ANOVA) and all peptides (with *p* \< 0.05) of an identified protein were included. For analysis of the proteins, the mean abundance of each protein across the experimental groups (e.g. Stage I samples from responders etc.) was calculated and those proteins with a ≥2.0-fold-change (FC) between the comparator groups were reported. For use in network and pathway analysis, however, a less stringent cut-off of ≥1.2-FC was used to allow for the study of systemic changes, as has been appropriate in similar studies using pathway and network approaches \[[@CR34]\].

Pathway and network analysis of proteomic datasets {#Sec7}
--------------------------------------------------

Proteins were analysed using the pathway enrichment and topological analysis tools in Ingenuity™ (Qiagen, US) \[[@CR35]\] to identify and visualise the canonical pathways which are differentially affected between Stages I and II of ACI. To allow for greater confidence in the pathway analysis, an independent platform, the Database for Annotation, Visualization and Integrated Discovery (DAVID) \[[@CR36]\], was used to analyse functional pathway based on the protein changes.

Validation of mass spectrometry using ELISA {#Sec8}
-------------------------------------------

Two proteins were selected to validate the MS findings because they: (1) had associated biological relevance to cartilage injury and repair; (2) showed consistent differential abundance between Stages I and II of ACI in non-responders versus responders; and (3) could be measured using available enzyme-linked immunosorbent assays (ELISAs). These proteins, matrix metalloproteinase 1 (MMP1) \[[@CR37]\] and S100 calcium binding protein A13 (S100-A13) \[[@CR38]\], were quantified using duo-set ELISAs (R&D systems, Wiesbardon, Germany) according to the manufacturer's instructions. Samples were assessed in duplicate and mean optical density values were used to calculate the protein concentration. SF was diluted 1:2 and 1:100 for the assessment of MMP1 and S100-A13, respectively. The protein concentration of each protein was normalised to total protein concentration. Statistical analysis was performed in GraphPad Prism version 6.0.

Results {#Sec9}
=======

Proteomic data has been deposited in the PRIDE ProteomeXchange and can be accessed using the identifier PXD005220 \[[@CR39]\].

Differential abundance of proteins in responders versus non-responders to ACI {#Sec10}
-----------------------------------------------------------------------------

Proteomic analysis identified that Ig kappa chain V-II region MIL demonstrated a +2.6-FC in non-responders versus responders to ACI in SF at Stage I (Fig. [1a](#Fig1){ref-type="fig"}). Nine proteins demonstrated differential abundance at Stage II between responders and non-responders (26S protease regulatory subunit 7, +2.3-FC; 26S proteasome non-ATPase regulatory subunit 13, +2.4-FC; ferritin light chain, +2.9-FC; platelet factor 4, +3.3-FC; thrombospondin-1, +3.4-FC; nucleosome assembly protein 1-like 1, +4.9-FC; cofilin-1, +7.1-FC; EH domain-containing protein 1, +7.3-FC; and T-complex protein 1 subunit eta, +8.4-FC) (Fig. [1a](#Fig1){ref-type="fig"}).Fig. 1Venn-Diagrams representing the proteins identified using label-free quantification proteomics which were differentially abundant (≥2.0-FC) in the SF (**a**) at Stage I (*SI*) or Stage II (*SII*) in responders (*R*) compared to non-responders (*NR*) to ACI, (**b**) showing increased (↑) or decreased (↓) abundance at Stage II compared to stage I of ACI in clinical responders (R) or non-responders (NR)

Differential abundance of proteins after controlled cartilage injury (Stage I versus Stage II) {#Sec11}
----------------------------------------------------------------------------------------------

When comparing Stage I with Stage II, 116 proteins were \>2.0-fold differentially abundant. Non-responders to ACI displayed a distinct and marked response to Stage I surgery, such that between Stages I and II, 33 proteins were upregulated and 59 downregulated, 12 of which demonstrated common expression change in clinical responders to ACI (Table [2](#Tab2){ref-type="table"}; Fig. [1b](#Fig1){ref-type="fig"}). Fifteen proteins were upregulated and nine proteins were downregulated between Stage I and Stage II in responders to ACI (Table [3](#Tab3){ref-type="table"}; Fig. [1b](#Fig1){ref-type="fig"}).Table 2Fold-change of proteins that are differentially expressed in the synovial fluid collected at Stage I compared to Stage II of the ACI procedure in clinical non-responders. Proteins shown in italic were validated using enzyme linked immunosorbant assayProteinFold changeDescriptionAccessionPerilipin-4Q96Q06--4.3Syntaxin-7O15400--3.9Fermitin family homolog 3Q86UX7--3.7Deoxynucleoside triphosphate triphosphohydrolase SAMHD1Q9Y3Z3--3.7PDZ and LIM domain protein 1O00151--3.6Sorting nexin-5Q9Y5X3--3.3Neuroblast differentiation-associated protein AHNAKQ09666--3.2Signal recognition particle 14 kDa proteinP37108--3.0Hyaluronan and proteoglycan link protein 3Q96S86--3.0Heterogeneous nuclear ribonucleoprotein KP61978--2.9ATP-citrate synthaseP53396--2.9Fatty acid-binding protein, epidermalQ01469--2.860S ribosomal protein L12P30050--2.7Fatty acid-binding protein, adipocyteP15090--2.6Insulin-like growth factor-binding protein 6P24592--2.6Protein canopy homolog 3Q9BT09--2.6Tripeptidyl-peptidase 1O14773--2.5PDZ and LIM domain protein 3Q53GG5--2.5Cellular nucleic acid-binding proteinP62633--2.5Bifunctional glutamate/proline-tRNA ligaseP07814--2.5Protein disulfide-isomerase A3P30101--2.4Peroxiredoxin-6P30041--2.4Tryptase alpha/beta-1Q15661--2.4Endoplasmic reticulum resident protein 29P30040--2.4Peroxiredoxin-1Q06830--2.4Na(+)/H(+) exchange regulatory cofactor NHE-RF1O14745--2.4Mitochondrial import inner membrane translocase subunit TIM14Q96DA6--2.4Mortality factor 4-like protein 1Q9UBU8--2.4Fructose-bisphosphate aldolase AP04075--2.3Microtubule-associated protein RP/EB family member 1Q15691--2.3Leucine zipper transcription factor-like protein 1Q9NQ48--2.3Transcription elongation factor A protein 1P23193--2.32\',3\'-cyclic-nucleotide 3\'-phosphodiesteraseP09543--2.3Histamine N-methyltransferaseP50135--2.3*Protein S100*-*A13*Q99584--2.3Acrosomal protein SP-10P26436--2.2AP-2 complex subunit betaP63010--2.2S-phase kinase-associated protein 1P63208--2.2High mobility group protein B3O15347--2.2Cytokine-like protein 1Q9NRR1--2.2Mitochondrial fission 1 proteinQ9Y3D6--2.2Filamin-AP21333--2.2Nuclear migration protein nudCQ9Y266--2.1Cathepsin KP43235--2.1Prostaglandin E synthase 3Q15185--2.1VinculinP18206--2.1Plastin-2P13796--2.1Coronin-1CQ9ULV4--2.1Ig heavy chain V-I region V35P23083--2.1Stress-induced-phosphoprotein 1P31948--2.1Putative phospholipase B-like 2Q8NHP8--2.1GelsolinP06396--2.0Spectrin beta chain, erythrocyticP11277--2.0StathminP16949--2.0Hsc70-interacting proteinP50502--2.040S Ribosomal proteinP23396--2.0Epidermal growth factor receptor substrate 15P4256622.5Hemoglobin subunit theta-1P091056.1C-type lectin domain family 11 member AQ9Y2405.6PeriostinQ150635.1Collagen alpha-1(I) chainP024524.7Spectrin alpha chain, erythrocytic 1P025494.0Collagen alpha-1(V) chainP209083.7Fibrinogen gamma chainP026793.5Collagen alpha-1(XII) chainQ997153.3Complement C1q tumor necrosis factor-related protein 3Q9BXJ43.1AdiponectinQ158483.0Adipocyte enhancer-binding protein 1Q8IUX73.0Latent-transforming growth factor beta-binding protein 1Q147663.0Fibrinogen beta chainP026753.0Chondroitin sulfate proteoglycan 4Q6UVK12.9Fibrinogen alpha chainP026712.8*Interstitial collagenase* (*MMP1*)P039562.7Secreted phosphoprotein 24Q131032.7Collagen alpha-2(V) chainP059972.6Ferritin light chainP027922.6C4b-binding protein alpha chainP040032.6Nucleobindin-1Q028182.4C4b-binding protein beta chainP208512.2Vitamin K-dependent protein SP072252.2FibronectinP027512.2ProsaposinP076022.1Integrin beta-like protein 1O959652.1Adipocyte plasma membrane-associated proteinQ9HDC92.1Cytoplasmic dynein 1 heavy chain 1Q142042.0Soluble scavenger receptor cysteine-rich domain-containing protein SSC5DA1L4H12.0F-actin-capping protein subunit betaP477562.0Mannan-binding lectin serine protease 1P487402.0Thrombospondin-3P497462.0Positive numbers denote an increase in the protein at Stage II; negative numbers denote a decrease in the protein at Stage II Table 3Proteins that are differentially expressed with a ≥2.0-fold-change in the synovial fluid collected at Stage I compared to Stage II of the ACI procedure in clinical respondersProteinFold changeDescriptionAccessionHeat shock protein 75 kDa, mitochondrialQ12931--470.0Microtubule-associated protein 1BP46821--17.2AdenosylhomocysteinaseP23526--3.7Complement factor H-related protein 3Q02985--2.8Mannose-1-phosphate guanyltransferase betaQ9Y5P6--2.7Peroxiredoxin-4Q13162--2.5Oxysterol-binding protein 1P22059--2.4Protein canopy homolog 3Q9BT09--2.1Spermatid perinuclear RNA-binding proteinQ96SI9--2.0Ferritin light chainP027922.2Secreted phosphoprotein 24Q131032.2Chondroitin sulfate proteoglycan 4Q6UVK12.3Collagen alpha-2(I) chainP081232.3Collagen alpha-1(V) chainP209082.526S protease regulatory subunit 6AP179802.7Collagen alpha-2(V) chainP059972.9Collagen alpha-1(I) chainP024523.3Spectrin alpha chain, erythrocytic 1P025494.1Histidine triad nucleotide-binding protein 1P497734.2Platelet factor 4P027764.2Alpha-1-acid glycoprotein 2P196524.3Protein 4.1P111714.3PeriostinQ150634.526S proteasome non-ATPase regulatory subunit 13Q9UNM64.6Positive numbers denote an increase in the protein at Stage II, negative numbers denote a decrease in the protein at Stage II

Identification of canonical pathways and protein networks associated with protein changes between Stage I and II {#Sec12}
----------------------------------------------------------------------------------------------------------------

Several canonical pathways were associated with the protein changes identified in both clinical responders and non-responders (Fig. [2](#Fig2){ref-type="fig"}). Figure [3](#Fig3){ref-type="fig"}, however, highlights the disparity in the proteome response to Stage I between clinical responders and non-responders, as a much greater number of functional/disease pathways were activated or inhibited in association with these differentially abundant proteins. Using Ingenuity software, canonical pathways that were most significantly connected with these protein changes in non-responders were Liver X Receptor/Retinoic X receptor (LXR/RXR) activation (*p* = 1.63 × 10^--7^), complement system (*p* = 9.33 × 10^--7^), and acute phase response signalling (*p* = 1.69 × 10^--6^) (Fig. [2](#Fig2){ref-type="fig"}). Independent pathway analysis of the proteins using DAVID also highlighted the complement system (*p* = 2.1 × 10^--6^) as highly associated with the protein changes seen between Stages I and II of ACI in non-responders.Fig. 2Canonical pathways altered in the synovial fluid of responders (**a**) and non-responders (**b**) at Stage I compared to Stage II of ACI, identified using Ingenuity analysis, based on proteins which were identified using label-free quantification proteomics (≥1.2-FC). The *bars* represent the significance of the canonical pathway as calculated by a right-sided Fisher's exact test; therefore, the tallest bars represent the canonical pathways that are the least likely to have been identified due to molecules being in the canonical pathway by random chance. Canonical pathways which are likely activated (based on the pattern of differentially abundant proteins) are shown in *orange* and pathways that are likely inhibited are shown in *blue* Fig. 3Heat map showing canonical pathway groupings for molecular and cellular functions altered in the synovial fluid of responders (**a**) and non-responders (**b**) at Stage I compared to Stage II of ACI, identified using Ingenuity analysis, based on proteins which were identified using label-free quantification proteomics (≥1.2-FC). *Squares* are coloured based on their *z* score, with *orange* being up at Stage II and *blue* being down at Stage II; the colour intensity indicates the prediction strength. The *z* score represents whether the up- or downregulation of the proteins within that function will lead to activation (positive *z* score) or inhibition (negative *z* score) of the function. *Black boxes* are shown around functions of biological interest: cellular movement, haematological system development and function, immune cell trafficking, and inflammatory response

The Stage I versus Stage II responder network consisted predominantly of proteins associated with connective tissue disorders (*p* = 8.2 × 10^--7^). In non-responders to ACI, however, the top scoring network included several proteins associated with the inflammatory response (*p* = 2.75 × 10^--5^) (Fig. [4](#Fig4){ref-type="fig"}). Transforming growth factor beta 1 (TGFβ1) and CCAAT/enhancer-binding protein beta were predicated to be the most significant upstream regulators associated with the networks of protein changes identified between Stages I and II in non-responders and responders, respectively (Table [4](#Tab4){ref-type="table"}). TGFβ was also predicted as an upstream regulator of the protein changes identified between Stages I and II in responders; therefore, it may be important in the regulation of protein response between Stages I and II, irrespective of outcome.Fig. 4Top scoring networks derived from the proteins with different abundance (≥1.2-FC) at Stage II compared to Stage I of the autologous chondrocyte implantation (*ACI*) procedure in those who responded well clinically (responders; **a**) and those who did not respond clinically (non-responders; **b**). *Red* nodes represent greater protein abundance at Stage II of ACI; *green* nodes represent lower protein abundance at Stage II of ACI; and *white* nodes represent inferred proteins which are not differentially expressed between Stage I and Stage II (based on label-free quantification proteomic analysis). The key to the features within the network is shown. *APOB* Apolipoprotein B-100, *CD3* T-cell surface glycoprotein CD3, *Ck2* Casein kinase 2, *COL1A1* Collagen alpha-1(I) chain, *COL1A2* Collagen alpha-2(II) chain, *C4* Complement C4, *DYNC1H1* Cytoplasmic dynein 1 heavy chain 1, *ERK* Mitogen-activated protein kinase 3, *ERP29* Endoplasmic reticulum resident protein 29, *F7* Coagulation factor VII, *FCN3* Ficolin-3, *GABRAPL2* Gamma-aminobutyric acid receptor-associated protein-like 2, *GBA* Glucosylceramidase, *GMFB* Glia maturation factor beta, *GPLD1* Phosphatidylinositol-glycan-specific phospholipase D, *HINT1* Histidine triad nucleotide-binding protein 1, *HDL*-*cholesterol* High density lipoprotein-cholesterol, *HMGB2* High mobility group protein B2, *HSP76* Heat shock protein 76, *IGFBP6* Insulin-like growth factor binding protein 6, *Jnk* Mitogen-activated protein kinase, *LCAT* Phosphatidylcholine-sterol acyltransferase, *LDL* Low-density lipoprotein receptor, *LTF* Lactotransferrin, *MASP1* Mannan-binding lectin serine protease 1, *MASP2* Mannan-binding lectin serine protease 2, *MYH10* Myosin-10, *MYLK* Myosin light chain kinase, smooth muscle, *NFkB complex* nuclear factor kappa-light-chain-enhancer of activated B cells complex, *PAM* Peptidyl-glycine alpha-amidating monooxygenase, *PDCD6IP* Programmed cell death 6-interacting protein, *PF4* Platelet factor 4, *PI3K complex* Phosphoinositide-3 kinase complex, *PLG* Plasminogen, *POSTN* periositin, *PSMA7* Proteasome subunit alpha type-7, *P38 MAPK* P38 mitogen-activated protein-kinases, *Rock* Rho-associated protein kinase 1, *RPL22* 60S ribosomal protein L22, *Rxr* retinoic X receptor, *STX7* Syntaxin-7, *Tgf* beta Transforming growth factor beta, *Vegf* Vascular endothelial growth factor Table 4Analysis of upstream regulators of interactome networks generated from protein changes between Stages I (SI) and II (SII) in either responders or non-responders to ACI were identified using Ingenuity Pathway Analysis softwareUpstream regulatorsActivation *z* score (SII v SI)*p* value of overlapTarget molecules in datasetNon-respondersTGFB1--1.5959.46E--10APOB,APOC2,APOE,CD44,COL1A1,COL1A2,COL5A1,COMP,CSPG4,CTSD,ECM1,FETUB,FN1,FTL,GSN,HINT1,HSPG2,HTRA1,IGFBP6,LCAT,MYLK,PCOLCE2,PDXK,POSTN,RAP1A,S100A4,TGFBIDYSFNP2.01E--09CFD,FN1,FTL,LCP1,LYZ,PROS1,S100-A13,S100A4MYC3.0462.20E--09ALDOA,ANXA5,CCT3,CD44,COL1A1,COL1A2,COL5A1,CSPG4,CTSD,ECM1,FN1,HSPA9,LYZ,NCL,NUCB1,NUDC,PAM,PTN,RPL22,RPL30,TFCOL9A11.3082.79E--09COMP,FN1,HSPG2,TGFBI,THBS4Beta-estradiol2.2715.01E--09ALDOA,APOE,CD44,COL1A1,COL1A2,COMP,CTSD,F7,FN1,GMFB,HSPA2,HSPA8,HSPA9,HTRA1,IGFBP6,LTF,LYZ,MYLK,PAM,PDIA3,QSOX1,RAP1A,RPS13,S100-A13,SLC9A3R1,TF,THBS4Lipopolysaccharide--0.1045.96E--09ANXA5,APOB,APOC2,APOE,CD44,CFD,COL1A1,COL1A2,COL5A1,CSPG4,FN1,GSN,HDGFRP3,HMGB2,HSPA8,HTRA1,ITIH2,LBP,LTF,LYZ,PARK7,PCOLCE,PCOLCE2,PDIA3,PLG,TFDihydrotestosterone--1.0911.03E--08ALDOA,APOE,CCT3,FN1,FTL,GSN,HINT1,LYZ,MYLK,NUCB1,PAM,POSTN,PROS1,RPL30,TFHRAS0.6232.52E--08CD44,COL1A1,COL1A2,ERP29,FN1,GSN,HSPA8,HTRA1,LYZ,MYH10,PDIA5,PLTP,POSTN,RPL30,S100A4KRAS2.2263.99E--08ALDOA,CD44,COL1A1,FN1,GBA,GSN,MYLK,PCOLCE,PDIA3,PSMA7,RNASE4,S100A4SMARCB1--1.1954.82E--08APOC4,CD44,COL1A1,COL1A2,GSN,LBP,POSTN,PTN,RAB14RespondersCEBPB--1.0672.03E--07APOB,CFD,COL1A1,COL1A2,F7,HSPA8,PLGFLI1NP3.82E--07COL1A1,COL1A2,HSPA8,PF4S-adenosylhomocysteineNP1.21E--06COL1A1,COL1A2SCXNP1.65E--06COL1A1,COMP,POSTNTgf beta (group)--1.4545.16E--06COL1A1,COL1A2,LCAT,POSTN,TGFBIENTPD5NP1.21E--05COL1A1,COL1A2MKXNP1.21E--05COL1A1,COL1A2GATA4NP2.86E--05COL1A1,COL1A2,POSTN,TGFBINilotinibNP3.39E--05COL1A1,COL1A2TBX5NP5.50E--05COL1A1,COL1A2,POSTNThe 10 upstream regulators with the lowest *p* values are demonstrated for both responders and non-responders. The *p* value of overlap is calculated based on the overlap between protein changes within the dataset with known targets of the transcriptional regulator, calculated using a Fisher's exact test. The activation *z* score can be used to infer likely activation states of the upstream regulators based on the direction of protein abundance change in the dataset, i.e. a negative activation *z* score indicates that the upstream regulator is downregulated at Stage II compared to stage I, thus eliciting the specific directions of protein changes of the target molecules at Stage II compared to Stage I of ACI. *NP* indicates no prediction of activation status could be generated by the software

Measurement of MMP1 and S100-A13 protein in SF by ELISA {#Sec13}
-------------------------------------------------------

MMP1 and S100-A13 protein abundance in SF from the same patient cohort was measured using ELISA. Biochemical assessment replicated the MS finding that SF MMP1 concentration is significantly increased at Stage II in non-responders (Stage I, 800 ± 889 pg/ml; Stage II, 7741 ± 8065 pg/ml (mean ± SD); *p* = 0.006; Mann-Whitney *U* test) (Fig. [5](#Fig5){ref-type="fig"}). However, measurement of MMP1 via ELISA also demonstrated a significant increase in concentration at Stage II compared to Stage I in responders to ACI (albeit to a lesser order of magnitude: Stage I, 655 ± 837 pg/ml; Stage II, 2672 ± 3576 pg/ml (mean ± SD); *p* = 0.039; Mann-Whitney *U* test) (Fig. [5](#Fig5){ref-type="fig"}). In this patient cohort, no correlation between Lysholm score and MMP1 could be demonstrated (*r* = 0.02; *p* = 0.94; Spearman's correlation).Fig. 5Two biologically relevant proteins, matrix metalloproteinase-1 (*MMP1*) and S100 calcium binding protein A13 (*S100*-*A13*), that were identified by proteomic analysis as differentially abundant in the SF of non-responders between Stages I (*SI*) and II (*SII*) of the *ACI* procedure were validated by ELISA. **a** The differential abundance as measured by label-free mass-spectrometry and by biochemical ELISA. MMP1 was measured by ELISA in the SF of (**b**) non-responders (*NR*) and (**c**) responders (*R*) to ACI at cartilage harvest (Stage I; *S1*) and chondrocyte implantation (Stage II; *S2*). S100-A13 was measured by ELISA in the SF of non-responders (**d**) and responders (**e**) to ACI

Biochemical quantification identified a significant decrease in S100-A13 expression at Stage II (94 ± 31 pg/ml (mean ± SD)) compared to Stage I (245 ± 123 pg/ml (mean ± SD); *p* =0.02; Mann-Whitney *U* test) of the ACI process in clinical non-responders and no significant difference in responders (Stage I, 200 ± 118 (mean ± SD); Stage II, 138 ± 93 (mean ± SD); *p* = 0.2; Mann-Whitney *U* test) thus validating MS findings (Fig. [5](#Fig5){ref-type="fig"}). To assess whether the differential abundance of S100-A13 identified between Stages I and II was genuinely only a response of clinical non-responders, further statistical analysis including only the paired Stage I (*n* = 7) and II (*n* = 6) samples was completed. The paired analysis also confirmed the MS findings, with non-responders having lower SF S100-A13 concentration at Stage II compared to Stage I (Stage I, 270 ± 113 (mean ± SD); Stage II, 116 ± 112 (mean ± SD); *p* = 0.03; Wilcoxon-matched pairs) and no significant difference in S100-A13 concentration between Stages I and II demonstrated in clinical responders (Stage I, 204 ± 127 (mean ± SD); Stage II, 140 ± 53 (mean ± SD); *p* = 0.22; Wilcoxon-matched pairs). Again, Lysholm score and S100-A13 concentration did not correlate in this cohort (*r* = 0.0002; *p* = 0.99; Spearman's correlation).

Discussion {#Sec14}
==========

The unbiased quantitative study of the human SF proteome is relatively limited \[[@CR14], [@CR15]\] and few studies are reported which identify novel biomarkers for the diagnosis of cartilage injury or for their prognostic or predictive value in the treatment of cartilage injuries \[[@CR16], [@CR18]\]. To our knowledge, only four studies have assessed SF or blood for biomarkers of cartilage injury treatment \[[@CR16], [@CR17], [@CR19], [@CR40]\] from which limited putative predictive markers have been identified.

The patient cohort used in this study presents an opportunity to explore which proteins are altered between individuals who have responded well to ACI and those non-responders whose joint function has deteriorated post-treatment. Although a non-responder is generally defined as an individual who does not demonstrate an improvement in Lysholm score of 10 or more points, we have been able to identify proteins that relate to the worst clinical outcomes in our cohort; in future studies, these protein changes will need to be explored further in non-responders with a lesser negative response to ACI. It would have been interesting to assess how cartilage regeneration related to clinical outcome in these patients; unfortunately, however, data regarding the quality and amount of repair tissue in the defect site post-treatment were not routinely collected for these patients.

Ideally, a biomarker that predicts response to cell therapy would be measured before the patient undergoes cartilage harvest. This study, however, demonstrated that only one protein displayed differential abundance between responders and non-responders at Stage I of the ACI procedure. Interestingly, the vast majority of differences in the proteomic profile of SF were evident between Stages I and II of the ACI procedure, particularly in non-responders to ACI. Analysis of the pathways that are altered between Stages I and II of ACI illustrates further the disparity in biological response to a controlled cartilage injury in clinical responders versus non-responders. This suggests that it may be the response of the patients to the cartilage harvest procedure at Stage I that proves to be the best predictor of clinical outcome.

One of the biologically relevant proteins identified that increased in the SF of non-responders at Stage II compared to Stage I of ACI was MMP1. Along with other MMP family members, it is overexpressed in many forms of arthritis \[[@CR37]\] and has been strongly associated with increased joint inflammation \[[@CR41], [@CR42]\]. Since MMP1 has cartilage degradation properties \[[@CR37]\], implanting chondrocytes into a joint with high levels of active MMP1 might be detrimental to any new cartilage formation. However, the ELISA used in this study assessed total MMP1 protein; therefore, additional studies to determine how much active MMP1 is present would be needed to further elucidate the mechanisms of action. Nonetheless, a higher absolute level of MMP1 found in the SF of non-responders at Stage II compared to Stage I of the ACI procedure is suggested to be predictive of a poor outcome, which could inform the second stage of the ACI procedure. For example, it may be that an individual with high levels of MMP1 at Stage II requires a tailored procedure and could benefit from delayed chondrocyte implantation to allow for dampening of inflammation or a coincidental treatment to reduce MMP1 activity specifically or to reduce joint inflammation.

Interestingly, S100-A13 abundance was found to be significantly lower in the SF from non-responders to ACI at Stage II compared to Stage I. This finding is completely novel since, despite six of these family members having been studied in cartilage (S100B \[[@CR43]\], S100-A2 \[[@CR44]\], S100-A4 \[[@CR45]\], S100-A8 \[[@CR46]\], S100-A9 \[[@CR46]\], and S100-A11 \[[@CR47]\]), we are unaware of any studies that have assessed the role of S100-A13 in cartilage or SF. S100-A13 therefore presents an attractive novel candidate for further study, not only to confirm its potential as a predictive biomarker but also to improve our biological understanding of the processes underlying cartilage injury and repair.

Despite MMP1 and S100-A13 both having potential as candidate biomarkers to determine whether or not a patient is suitable to continue to the second stage of ACI, it is unlikely that any individual biomarkers will be sufficient to determine which patients are suitable candidates for a cartilage repair therapy. Patient demographics have already been identified which are known to pre-dispose to ACI failure, including gender, body mass index, age, and the size of the cartilage lesion \[[@CR10], [@CR25], [@CR48]\]. Our long-term aim is to work towards the development of a clinical prediction model which will likely include known risk factors, along with a panel of biomarkers that, together, can predict the response of an individual to ACI. This exploratory study has indicated a plethora of potential SF biomarkers that may contribute to the development of such a clinical prediction model. Other studies have also indicated that the quality of the culture-expanded autologous chondrocytes affects patient clinical outcome (higher percentage positivity of CD44-expressing cells and increased collagen type II and aggrecan expression correlate with good clinical outcome, whereas lower cell viability correlates with poor clinical response to ACI) \[[@CR28], [@CR49], [@CR50]\]. Therefore, ideally, the quality of ACI cells prior to implantation at Stage II, along with known demographic risk factors, would be considered as part of a clinical prediction matrix. We have already shown that the absence of detectable aggrecanse-1 is able to predict ACI success, and that lower age and the use of a collagen patch are also indicators of ACI success \[[@CR19]\]; consequently, markers identified within this study may be added to this developing predictive model.

Many of the protein shifts observed in the SF between Stages I and II of the ACI procedure are likely to be associated with acute mechanisms of cartilage healing in response to the cartilage harvest, which could be considered as a controlled injury. Furthermore, the differences observed in this shift when comparing responders and non-responders to ACI could be a result of differences in the mechanisms of action and/or the rate/magnitude of an individual's innate capacity for cartilage healing. Our evaluation of the SF proteome shift both before and after such a defined injury represents a period of acute response to injury and could therefore be considered as a model of short-term natural healing in humans. In order to validate that the response observed in this model is due to the cartilage harvest and not the arthroscope procedure, an appropriate control group should be evaluated. In future work we will aim to test potential biomarkers in a stem cell treatment group which will similarly undergo a Stage I arthroscope (but without a cartilage harvest) followed by cell implantation at Stage II in a comparable time frame.

Pathway and network analyses were performed to try and elucidate the functional implications of the observed proteome shift. Confidence can be taken from these findings, as pathways of known biological relevance were identified. For example, the complement system, which was activated in non-responders to ACI, can lead to cartilage degradation \[[@CR47]\]. Other biologically relevant pathways that were identified include the acute phase response, which in contrast was dysregulated in non-responders. Dysregulation of the acute phase response has previously been associated with the proteome of OA knees \[[@CR51]\], and serum amyloid-A, a key acute-phase protein, is increased in abundance in the SF and blood of individuals with OA \[[@CR52]\]. Both of these observations indicate that the acute-phase response may be a contributing factor as to why some individuals do not respond well to ACI and there is merit in further studying how this pathway is altered in these individuals.

Interestingly, TGFβ1 was suggested as the most potent potential upstream regulator of the network of non-responder SF protein response to ACI. TGFβ1 is suggested to regulate twenty-seven of the network proteins, and therefore manipulation of this biological network via TGFβ1 may serve as a potential method to influence response to ACI in clinical non-responders. It is strongly established that TGFβ signalling is highly influential on the development and progression of OA \[[@CR53]\]. Specifically, TGFβ is important in the regulation of chondrocyte hypertrophy and maturation \[[@CR54]\]. Mutations in the TGFβ1 gene, as well as genetic variation in other members of the TGFβ signalling pathway, have been related to OA development \[[@CR53]\]. Moreover, in transgenic animals which overexpress the type-II TGFβ receptor, chondrocytes in the superficial zone of the cartilage are hypertrophic with increased type X collagen expression and decreased proteoglycans \[[@CR55]\]. Together, these observations highlight the importance of TGFβ for chondrocyte homeostasis; therefore, in non-responders to ACI, perhaps aberrant upstream expression of TGFβ contributes to their poor cartilage formation.

Canonical pathway analysis has also highlighted more novel pathway modifications within non-responders to ACI such as inhibition of LXR/RXR. Dimerisation of RXRs and LXR initiates transcriptional regulation that is involved in the regulation of inflammation \[[@CR56]\]. Interestingly, proteomic profiling of the SF from osteoarthritic shoulders has highlighted dysregulation of the LXR/RXR pathway in response to OA \[[@CR57]\], and agonism of the LXR/RXR pathway has previously been suggested as a therapeutic target for OA since human cartilage explants treated with a synthetic LXR agonist showed reduced cytokine-mediated degradation of proteoglycans \[[@CR58]\]. Although further study is required to determine how inhibition of the LXR/RXR pathway may lead to a poor clinical response to ACI, it may be that these individuals are demonstrating a more 'osteoarthritic' phenotype, perhaps meaning that ACI may be insufficient to repair their cartilage injury.

The most striking biologically relevant canonical pathway groupings that were upregulated in non-responders to ACI were inflammatory and immune responses. This strengthens the suggestion that poor response to ACI in these individuals may be attributed to the chondrocytes being implanted into an unsuitable, highly inflammatory environment. Alternatively, it may indicate that these individuals have a more pronounced immune reaction to cartilage injury in general, and that this is an indicative response of 'poor healers'.

Conclusion {#Sec15}
==========

We have identified proteins that are altered within the SF following cartilage injury and ACI, and have highlighted proteome changes in response to the cartilage harvest procedure in ACI which relates to clinical outcome. These protein changes represent a plethora of potential predictive biomarkers that, with further validation, could help in the identification of patients who are not suited to ACI or perhaps any cartilage repair procedure. Pathway and network analyses of the altered SF proteome have highlighted both known and novel biological pathways that may be implicated in the response to Stage I of ACI. These data present an opportunity for future study which could vastly improve our knowledge of how a joint responds to cartilage injury and how that may differ between individuals who do or do not have the capacity for cartilage repair.
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